Integral Molecular Inc.

Integral Molecular Inc., a Philadelphia-based biotechnology company, delivers membrane protein research services, monoclonal antibody discovery and characterization, and viral assay development to federal health and defense agencies as a prime contractor (94% of awards) under small-business set-asides and full-and-open competition, with no SBA certifications on record. The company operates primarily on SBIR contracts, purchase orders, and definitive contracts focused on therapeutic antibody development, immunologic reagent production, and specificity screening for biopharmaceutical programs.

Customer concentration is extreme: the National Institute of Allergy and Infectious Diseases (NIAID) anchors 13 awards worth $37.1 million of the vendor's $37.7 million combined potential value across all 54 awards — 99% of dollars tracked in the source. The National Cancer Institute, the National Institute of General Medical Sciences, the National Institute of Environmental Health Sciences, and the National Institute of Child Health and Human Development round out the NIH customer base. Defense and other civilian agencies (Department of the Army, Defense Health Agency, CDC Pittsburgh) account for fewer than five awards combined, totaling less than $75 thousand in potential value. The portfolio spans 17 distinct federal agencies, but NIH controls the footprint decisively.

Recent activity shows flat-to-declining volume: five awards in 2022, six in 2023 and 2024, four in 2025, and one in 2026 (as of late September). Four awards totaling $1.5 million in combined potential value face ultimate completion within the next twenty-four months, presenting modest recompete exposure. Dollar volume obligated ($67.9 million) exceeds combined potential value ($37.7 million), indicating that multiple task orders and contract modifications have added dollars beyond original ceiling values.

On SCI-reportable federal service contracts, Integral Molecular invoiced $6.7 million across FY2022–FY2025, with $1.4 million (FY2022), $1.8 million (FY2023), $2 million (FY2024), and $1.5 million (FY2025). The vendor delivered roughly 6.1 to 9.9 FTEs per fiscal year under these contracts. Government-paid hourly rates on SCI prime records ran a median of $94.36/hr, with senior labor reaching $273.90/hr at the 90th percentile and entry-level work starting near $48.98/hr. SCI figures represent a narrow slice of the vendor's total federal invoicing; the $8.077 million NIAID B cell epitope discovery contract alone (running through September 2029) demonstrates that Integral Molecular's federal services footprint extends well beyond the $150,000 SCI threshold.

Integral Molecular operates as a prime on nearly all work: across SCI-reportable prime contracts, subcontractors account for just 4% of total contractor hours, and only four named subcontractors appear across the full portfolio. As a subcontractor, the company performs under Advanced Technology International (provision of renilla luciferase reporter virus particles under a Battelle IDIQ) and under Medical Science & Computing, LLC (clinical sample testing for SARS-CoV-2 vaccine candidates). The vendor's subcontracting posture is minimal and largely passive — it is not a feeder to larger primes.

Recent prime contract work includes a $1.5 million NIAID SBIR Phase II award (June 2025) for antibody reagents supporting immunologic analysis of underrepresented mammalian models, running through May 2028; an $8.077 million NIAID cost-plus-fixed-fee definitive contract (September 2024) for B cell epitope discovery and characterization against Rift Valley fever virus, Crimean-Congo hemorrhagic fever virus, and enterovirus D68, through September 2029; and multiple purchase orders for membrane proteome array screening services, laboratory supplies, and reporter virus particles from NIAID, the National Cancer Institute, and the National Institute of Child Health and Human Development.

Integral Molecular holds a robust federal grant footprint as a prime recipient under the NIH. Recent cooperative agreements and project grants include a $16.2 million NIAID cooperative agreement (August 2025) for generation of pan-reactive antibody and cytokine reagents for bat immunologic analysis, running through June 2030; an NIGMS project grant (September 2024) for development of a membrane proteome array as an FDA-accepted drug development tool for biotherapeutic safety screening; an NIGMS project grant (May 2023) for high-throughput mRNA-based antibody discovery against understudied membrane proteins (G protein-coupled receptors and ion channels) as part of the NIH Illuminating the Druggable Genome initiative, extending through January 2028; an NIAID project grant (July 2024) for development of rapid reporter viruses for pandemic virus neutralization assays; a National Cancer Institute grant (June 2022) for claudin-6 monoclonal antibodies targeting solid tumors; and a National Institute on Aging grant (June 2022) for identification of cellular aging regulators in Alzheimer's disease prevention. Integral Molecular acts as prime recipient on all named grants; no sub-recipient relationships appear in the source.

The vendor competes under Total Small Business set-asides on SBIR Phase I and Phase II programs and under full-and-open procurement on contracts and grants that do not invoke set-asides. No 8(a), HUBZone, SDVOSB, WOSB, or other SBA certifications are present in the award record. The portfolio's NAICS concentration reflects the biotechnology and laboratory services mission: Research and Development in Biotechnology (6 awards), Testing Laboratories and Services (3 awards), and Research and Development in Physical and Life Sciences (3 awards) lead the categorization.